top of page

Osteoporosis       

An overview of signaling

By Nicole Mamprejew

What is Osteoporosis?

We consider bone to be infallible, especially since it protects our most vital organs, but imagine a cell signaling error leading to the degeneration of your bone - this is the reality of osteoporosis. Many think that bone is static, however bone is constantly remodeling itself. Remodeling is the process by which osteoclasts absorb bone and osteoblasts support the growth of new bone – errors in this remodeling process are what lead to the onset of osteoporosis, along with a handful of other environmental factors (1). Osteoporosis is characterized as decreased bone mass and strength, leading to frail bones (1).

Some of the factors associated with osteoporosis include hormonal imbalance, especially related to menopause, as well as increased thyroid hormone levels, and decreased calcium intake (2). These factors combine to pose a danger for our aging population (2). Brittle bones are complication of osteoporosis, which leaves older adults at an increased risk for fractures associated with falls (2).

 

There is a strong correlation between menopause in Caucasian women and the onset of osteoporosis (2). Menopause is associated with decreased levels of estrogen – the differentiation of osteoclasts is inhibited by estrogen (2). It is important to keep in mind that osteoclasts are the cells that absorb bone in the remodeling process. At the onset of menopause, the decreased levels of estrogen reduce the inhibitory effect on osteoclast, leading to over-activity and bone degeneration. 

 

While the exact details of the molecular pathway involved in osteoporosis are not quite known, there is strong evidence for the involvement of the RANK pathway and Wnt Pathway (1, 3). The ligand for the RANK receptor is secreted by osteocytes, which are located in mature bone - the RANK ligand (RANKL) binds to the RANK receptor on the osteoclast precursor, leading to the differentiation of osteoclasts (1). With the Wnt pathway, the Wnt ligand is sequestered away from the receptor leading to the absence of transcriptional factors that promote the differentiation of osteoblasts, that help to grow bone (1). These pathways are elaborated on below to provide an in-depth look as to how cell signaling leads to osteoporosis. 

 

With a partial hormonal basis of this bone disorder, it is difficult to create targeted therapies, considering estrogen circulates systemically as a hormone. By providing patients with an estrogen replacement therapy to increase estrogen levels, the estrogen signals in areas that are not specific to bone and as a result of this endocrine signaling, patients are at an increased risk for breast cancer (4). An immunological approach to treatment is in the process of being explored, because interleukinsare also involved in the differentiation process of osteoblasts, which are involved in inflammation (5).

Symptoms 

The symptoms of osteoporosis do not always manifest themselves until an acute medical situation occurs. Osteoporosis is frequently detected after an individual experiences a bone fracture, but it is often asymptomatic (2, 4). 

​

Bone fractures of osteoporotic patients are often more painful and pain levels greatly vary based on the location of the break (3). Spinal fractures are associated with severe pain that radiates to the sides of the body (3, 4). Osteoporosis is also related to collapsed vertebrae and stooped posture, with a loss of height (3). The hunched posture of older females is often attributed to osteoporosis affecting their spine (3, 4). Hip fractures are often a result of falls, and are marked with slow healing time, due to over activity of osteoclasts (3, 4). Brittle bone makes surgical repairs difficult and leads to poor prognosis in patients.

​

Stress fractures are also common in patients with osteoporosis, and these are fractures that result from activities of daily life, including walking and climbing stairs (2, 4). Bone is weak and subject to break from typical stresses to the human body (2, 4).

 

Bone fractures in older adults are marked with significant decreases in quality of life and can even lead to permanent disability (4). They are often associated with increased risks of falls, further fractures, and even death (2, 3, 4). It is estimated that 20% of females with hip fractures die within two years (4). Preventative measures are critical in addressing osteoporosis. â€‹

​

Below you will be able to see how normal signaling leads to healthy bone remodeling, as well as how disruptions in cell signaling lead to brittle bone, as well as the other symptoms involved in osteoporosis. 

Normal Bone Formation and Resorption

Osteoporosis

Normal Bone Formation and Resorption 

It has been described that normal bone formation is a synergistic process medicated by osteoclasts and osteoblasts. The two types of cells form as a result of cell signaling. 

​

The RANK Pathway is related to differentiation, proliferation, and survival of osteoclasts and osteoclast formation is as follows – a Pre-Osteoclast with a RANK receptor, binds RANKL (3). This leads to an increase in nuclear factor-kB (NF-kB), a complex that aids in transcription of DNA and increases survival (3, 5). This is significant because the Pre-Osteoclasts bind to bone where the maturation into an Osteoclast occurs, and complexes like NF-kB promote the survival of the precursor (3, 5). 

​

The Wnt Pathway is related to a large family of glycoproteins that are involved in proliferation, differentiation, survival, migration, and apoptosis (5). The main focus will be on the canonical Wnt Pathway which involves Wnt and Beta-catenin. Wnt binds to a transmembrane protein called Frizzled which associates with low density lipoprotein receptor-related protein 5 and 6, more commonly known as LRP5/6 (5). Once this complex is activated, Axin is recruited which is a scaffold protein (5). This complex results in the inactivation glycogen synthase kinase 3 Beta (GSK-3B), and this is significant because this disallows proteasomes from degrading B-catenin; B-catenin can then localize into the nucleus and act as a transcription factor by associating with T-cell factor (TCF) and lymphoid-enhancer binding factor (LEF) (5). Upregulation of osteoblast formation occurs as a result. 

​

Osteoblasts and osteoclasts bind to bone, where old bone is degenerated and new bone is formed, guaranteeing the efficacy of our skeleton. 

Signal Dysfunction and Osteoporosis

You are likely questioning how changes at the cellular level lead to the systemic disruption of skeletal system. In healthy bone we see osteoblasts and osteoclasts working together to efficiently remodel bone, and associated with that are appropriate levels of signals leading to differentiation of these cells. In osteoporosis, there is a disruption caused by imbalanced signaling of transcription factors. 

​

Let's dive into the cell! Beginning with the RANK Pathway, RankL binds to the Rank Receptor on the surface of the cell. TNF receptor associated factor 6 (Traf6) associates with this complex leading to the association of Tak1, Tab1, and Tab2 in a complex (5). This complex promotes signaling and leads to the activation of IKKs which are a complex of catalytic kinase subunits and scaffold proteins that lead to the activation of NF-kB and localization of NF-kB into the nucleus (6). The IKK complex consists of IKK-alpha and IKK-beta along with a regulatory subunit that work to phosphorylate, activate kinase subunits and localize NF-kB to the nucleus (6). The localization leads to signaling that increases the transcription factors related to osteoclast differentiation (5). 

 

It is suspected that increased amounts of RANKL are seen due to decreased levels of estrogen in females experiencing menopause (3). By this pathway, we see an increase in osteoclast differentiation. This is only half of the equation, however. A lack of osteoblasts also contributes to the onset of osteoporosis. 

 

In the Wnt Pathway, decreased differentiation of osteoblasts is as a result of decreased Wnt available for binding to initiate the cascade (7). When Wnt doesn’t bind to the Frizzled/Disheveled complex, LRP5/6 fails to associate with this complex (1, 7). In this case, B-catenin is phosphorylated by GSK-3 (glucose synthase kinase-3), which marks it for degradation (1,7). GSK-3 is part of a complex including Axin and APC (7). A proteasome degrades B-catenin, which leads to the absence of nuclear localization of B-catenin (1, 7). Normally B-catenin would enter the nucleus and displace corepressors leading to increased transcription – lack of B-catenin leads to the corepressors staying in place and no transcription (7). This illustrates how lack of Wnt leads to the inhibition of a cascade that typically results in osteoblast differentiation. 

 

The brittle, porous bone that results from an imbalance in remodeling is associated with the pathology in osteoporosis. This brittle bone fractures easily and in turn can lead to many complications, including difficulty in surgical repair of the fracture, infection, pain, and is associated with increasing fractures in the future (2, 4). 

Therapeutic Interventions 

References

(1) Manolagas, S. C. (2014). Wnt signaling and osteoporosis. Maturitas, 78(3), 233-7. Click for link to article.

 

(2) Osteoporosis. (2016, July 06). Retrieved April 17, 2018, from https://www.mayoclinic.org/diseases-conditions/osteoporosis/symptoms-causes/syc-20351968

​

(3) McClung, M. (2007). Role of RANKL inhibition in osteoporosis. Arthritis Research & Therapy, 9(3). Click for link to article.

​

(4) Shiel, W. C. (2018, March 18). Osteoporosis. Retrieved from https://www.medicinenet.com/osteoporosis/article.htm#osteoporosis_facts 

​

(5) Jules, J., Ashley, J. W., and Feng, X. (2010). Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. Expert Opinion on Therapeutic Targets, 14(9), 923-934. Click for link to article.

​

(6) Israël, A. (2010). The IKK complex, a central regulator of NF-κB activation. Cold Spring Harbor Perspectives in Biology, 2(3). http://doi.org/10.1101/cshperspect.a000158

 

(7) Datta, H. K., Ng, W. F., Walker, J. A., Tuck, S. P., & Varanasi, S. S. (2008). The cell biology of bone metabolism. Journal of Clinical Pathology, 61, 577-587. Click for link to article.

​

(8) Sambrook, P., and Cooper, C. (2006). Osteoporosis. The Lancet, 367(9527), 2010-2018. Click for link to article.

​

(9) Drake, M. T., Clarke, B. L., & Khosla, S. (2008). Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clinic Proceedings. Mayo Clinic, 83(9), 1032–1045. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667901/

​

​

Diagram Inspired From:

​

RANK Signaling in Osteoclasts. (n.d.). Retrieved April 17, 2018, from https://www.thermofisher.com/us/en/home/life-science/antibodies/antibodies-learning-center/antibodies-resource-library/cell-signaling-pathways/rank-signaling-osteoclasts.html

​

An Overview of Wnt Signaling Pathways. (n.d.). Retrieved April 17, 2018, from https://www.rndsystems.com/resources/posters/overview-wnt-signaling-pathways

bottom of page